(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.
Aptevo Therapeutics's earnings in 2025 is -$23,704,000.On average, 1 Wall Street analyst forecast APVO's earnings for 2025 to be -$128,450,995, with the lowest APVO earnings forecast at -$128,450,995, and the highest APVO earnings forecast at -$128,450,995. On average, 1 Wall Street analyst forecast APVO's earnings for 2026 to be -$117,503,467, with the lowest APVO earnings forecast at -$117,503,467, and the highest APVO earnings forecast at -$117,503,467.
In 2027, APVO is forecast to generate -$81,336,078 in earnings, with the lowest earnings forecast at -$81,336,078 and the highest earnings forecast at -$81,336,078.